Skip to main content
SpringerLink
Log in

Spontaneous regression of meningiomas after interruption of nomegestrol acetate: a series of three patients

  • Original Article - Tumor - Meningioma
  • Published:
Acta Neurochirurgica Aims and scope Submit manuscript

Abstract

Background

The relationship between increased meningioma incidence and growth and long-term hormonal therapy with cyproterone acetate (CPA) in women has been recently established in literature. Following the raise in awareness from hormonal treatment, we describe a potential relationship between the progesterone agonist nomegestrol acetate (NOMAC) and meningioma growth.

Methods

After implementation of a screening protocol to detect potential interactions between hormonal exposure and occurrence of meningioma, we identified patients taking NOMAC and newly diagnosed with a meningioma. NOMAC was stopped and those patients were followed tightly both clinically and radiologically. Retrospective volumetric analysis of the tumors was performed on the imaging.

Results

Three patients were identified for the study. After cessation of the NOMAC, tumor shrinkage was documented for all meningiomas within the first month. Up to 70% of tumor volume reduction was observed during the first year of follow-up in one of them. None of the patients developed new symptoms.

Conclusion

We report the first cases of meningiomas responsiveness to discontinuation of hormonal therapy with NOMAC. Similarly to cases associated with long-term CPA intake, tumor reduction, and improvement of clinical symptoms can be observed after cessation of NOMAC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Anda T, Honda M, Ishihara T, Kamei T (2014) Progression of intracranial meningioma during luteinizing hormone-releasing hormone agonist treatment for prostate cancer: case report. Neurol Med Chir 54:327–330

    Article  Google Scholar 

  2. Bernat AL, Bonnin S, Labidi M, Aldahak N, Bresson D, Bouazza S, Froelich S (2018) Regression of giant olfactory groove meningioma and complete visual acuity recovery after discontinuation of cyproterone acetate. J Ophthalmic Vis Res 13:355–358

    Article  PubMed  PubMed Central  Google Scholar 

  3. Bernat AL, Oyama K, Hamdi S, Mandonnet E, Vexiau D, Pocard M, George B, Froelich S (2015) Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients. Acta Neurochir 157:1741–1746

    Article  PubMed  Google Scholar 

  4. Botella C, Coll G, Lemaire JJ, Irthum B (2015) Intra cranial meningiomas and long term use of cyproterone acetate with a conventional dose in women. A report of two cases of tumor decrease after treatment withdrawal. Neuro-Chirurgie 61:339–342

    Article  CAS  PubMed  Google Scholar 

  5. Cebula H, Pham TQ, Boyer P, Froelich S (2010) Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient. Acta Neurochir 152:1955–1956

    Article  PubMed  Google Scholar 

  6. Custer BS, Koepsell TD, Mueller BA (2002) The association between breast carcinoma and meningioma in women. Cancer 94:1626–1635

    Article  CAS  PubMed  Google Scholar 

  7. Durmaz R, Deliorman S, Isiksoy S, Uyar R, Tel E (1999) Luteinizing hormone releasing hormone increases proliferation of meningioma cells in vitro. Arch Physiol Biochem 107:286–291

    CAS  PubMed  Google Scholar 

  8. Gil M, Oliva B, Timoner J, Macia MA, Bryant V, de Abajo FJ (2011) Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study. Br J Clin Pharmacol 72:965–968

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Goncalves AM, Page P, Domigo V, Meder JF, Oppenheim C (2010) Abrupt regression of a meningioma after discontinuation of cyproterone treatment. AJNR Am J Neuroradiol 31:1504–1505

    Article  CAS  PubMed  Google Scholar 

  10. Hirota K, Fujita T, Akagawa H, Onda H, Kasuya H (2014) Spontaneous regression together with increased calcification of incidental meningioma. Surg Neurol Int 5:73

    Article  PubMed  PubMed Central  Google Scholar 

  11. Huang Q, Chen X, Zhu Y, Cao L, Riviere JE (2015) Pharmacokinetics, tissue distribution, and excretion of nomegestrol acetate in female rats. Eur J Drug Metab Pharmacokinet 40:435–442

    Article  CAS  PubMed  Google Scholar 

  12. Kalamarides M, Peyre M (2017) Dramatic shrinkage with reduced vascularization of large meningiomas after cessation of progestin treatment. World Neurosurg 101:814.e7–814.e10

    Article  Google Scholar 

  13. Kerschbaumer J, Freyschlag CF, Stockhammer G, Taucher S, Maier H, Thome C, Seiz-Rosenhagen M (2016) Hormone-dependent shrinkage of a sphenoid wing meningioma after pregnancy: case report. J Neurosurg 124:137–140

    Article  PubMed  Google Scholar 

  14. Khanna RK, Arsene S, Velut S, Zemmoura I, Gaillot K, Pisella PJ, Le Lez ML (2017) Spheno-orbital meningioma during pregnancy: case report of a 37-year-old woman. J Fr Ophtalmol 40:e361–e366

    Article  CAS  PubMed  Google Scholar 

  15. Lee KL, Terris MK (2003) Luteinizing hormone-releasing hormone agonists and meningioma: a treatment dilemma. Urology 62:351

    PubMed  Google Scholar 

  16. Lello S (2010) Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy. Drugs 70:541–559

    Article  CAS  PubMed  Google Scholar 

  17. Li Q, Coulson H, Klaassen Z, Sharma S, Ramalingam P, Moses KA, Terris MK (2013) Emerging association between androgen deprivation therapy and male meningioma: significant expression of luteinizing hormone-releasing hormone receptor in male meningioma. Prostate Cancer Prostatic Dis 16:387

    Article  CAS  PubMed  Google Scholar 

  18. Lusis EA, Scheithauer BW, Yachnis AT, Fischer BR, Chicoine MR, Paulus W, Perry A (2012) Meningiomas in pregnancy: a clinicopathologic study of 17 cases. Neurosurgery 71:951–961

    Article  PubMed  Google Scholar 

  19. Marques P, Skorupskaite K, George JT, Anderson RA (2000) Physiology of GNRH and gonadotropin secretion https://www.ncbi.nlm.nih.gov/books/NBK279070/. Accessed 20 Dec 2018

  20. Mueck AO, Sitruk-Ware R (2011) Nomegestrol acetate, a novel progestogen for oral contraception. Steroids 76:531–539

    Article  CAS  PubMed  Google Scholar 

  21. Olson JJ, Beck DW, Schlechte J, Loh PM (1986) Hormonal manipulation of meningiomas in vitro. J Neurosurg 65:99–107

    Article  CAS  PubMed  Google Scholar 

  22. Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro-oncology 19:v1–v88

    Article  PubMed  PubMed Central  Google Scholar 

  23. Perrot-Applanat M, Groyer-Picard MT, Kujas M (1992) Immunocytochemical study of progesterone receptor in human meningioma. Acta Neurochir 115:20–30

    Article  CAS  PubMed  Google Scholar 

  24. Perry A, Cai DX, Scheithauer BW, Swanson PE, Lohse CM, Newsham IF, Weaver A, Gutmann DH (2000) Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol 59:872–879

    Article  CAS  PubMed  Google Scholar 

  25. Pravdenkova S, Al-Mefty O, Sawyer J, Husain M (2006) Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. J Neurosurg 105:163–173

    Article  CAS  PubMed  Google Scholar 

  26. Tsutsui T, Miyashita K, Sabit H, Fukui I, Hayashi Y, Mizokami A, Ikeda H, Nagatani H, Nakada M (2016) Acute progression of recurrent meningioma during luteinizing hormone-releasing hormone agonist treatment for prostate cancer. World Neurosurg 91:670.e671–670.e676

    Article  Google Scholar 

  27. Yang LP, Plosker GL (2012) Nomegestrol acetate/estradiol: in oral contraception. Drugs 72:1917–1928

    Article  CAS  PubMed  Google Scholar 

  28. Yilmaz A, Kizilay Z, Sair A, Avcil M, Ozkul A (2016) Spontaneous regression of an incidental spinal meningioma. Open Access Maced J Med Sci 4:128–130

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Lariboisiere Hospital, University of Paris Diderot, 2 rue Ambroise Paré, 75010, Paris, France

    Thibault Passeri, Pierre-Olivier Champagne, Anne-Laure Bernat, Shunya Hanakita, Henri Salle, Emmanuel Mandonnet & Sébastien Froelich

Authors
  1. Thibault Passeri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pierre-Olivier Champagne
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne-Laure Bernat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shunya Hanakita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Henri Salle
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Emmanuel Mandonnet
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sébastien Froelich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre-Olivier Champagne.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (name of institute/committee) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Patient consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Tumor - Meningioma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Passeri, T., Champagne, PO., Bernat, AL. et al. Spontaneous regression of meningiomas after interruption of nomegestrol acetate: a series of three patients. Acta Neurochir 161, 761–765 (2019). https://doi.org/10.1007/s00701-019-03848-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00701-019-03848-x

Keywords

Search

Navigation